Clinical and hematological improvement in a patient receiving danazol therapy for myelofibrosis with myeloid metaplasia
Case report
OA: closed
CC0
⤵ 5 in-corpus citations
AI-generated summary
Danazol therapy improved severe cytopenia, reduced myeloid metaplasia, and was well-tolerated in a patient with myelofibrosis and myeloid metaplasia.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
We report the positive effect of danazol on clinical and hematological data in a patient with myelofibrosis and myeloid metaplasia. Severe cytopenia was corrected within 2 months and was maintained for an additional 2-month period. Myeloid metaplasia (lymph nodes and skin lesions) was greatly reduced. The patient experienced no side effects. We propose further trials to confirm the utility of this agent in this disease.
My notes (saved in your browser only)
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
Cited by (5)
- Danazol – możliwości wykorzystania w leczeniu chorób hematologicznych 2014
- Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients 2005
- Danazol treatment of idiopathic myelofibrosis with severe anemia 2000
- Treatment of agnogenic myeloid metaplasia with danazol: A report of four cases 1996
- A review of 76 patients with myelodysplastic syndromes treated with danazol 1994
Source provenance
- openalex
- last seen: 2026-05-10T10:50:55.528521+00:00
- pubmed
- last seen: 2026-10-08T21:12:08.185882+00:00
License: CC0
· commercial use OK